Literature DB >> 20151856

Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects?

D M Murphy1, I A Forrest, D Curran, C Ward.   

Abstract

IMPORTANCE OF THE FIELD: The macrolides are a class of antibiotics widely prescribed in infectious disease. More recently, there has been considerable interest in potential indications for these agents, in addition to their simple antibacterial indications, in a number of lung pathophysiologies. AREAS COVERED IN THIS REVIEW: Demonstrated clinical efficacy of macrolides in diseases such as diffuse panbronchiolitis was difficult to ascribe to a direct antimicrobial action. More recently, positive experiences in dealing with post-transplant bronchiolitis obliterans syndrome suggests that other chronic lung diseases may benefit from macrolide therapy. This is important, as the treatment options for such diseases are often very limited. In this review, potential antibiotic and non-antibiotic beneficial actions of macrolide therapy are discussed and conclusions drawn from a limited but growing literature. WHAT THE READER WILL GAIN: The reader will gain an overview of lung diseases that may benefit from macrolides, and a consideration of the possible mechanisms underlying such benefit. TAKE HOME MESSAGE: The key message from our review is that this class of agents may prove to be a useful therapeutic option for a range of respiratory diseases, but that further trials and mechanistic studies are required to clarify their role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151856     DOI: 10.1517/13543781003636480

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

1.  Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa.

Authors:  Isabel Pérez-Martínez; Dieter Haas
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 2.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

3.  A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.

Authors:  Paul A Corris; Victoria A Ryan; Therese Small; James Lordan; Andrew J Fisher; Gerard Meachery; Gail Johnson; Chris Ward
Journal:  Thorax       Date:  2015-02-24       Impact factor: 9.139

4.  Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis.

Authors:  Kirtikumar Upadhyay; Basu Hiregoudar; Elizabeth Meals; Boyce Keith English; Ajay J Talati
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

5.  Determination of Lekethromycin, a Novel Macrolide Lactone, in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study.

Authors:  Hongzhi Xiao; Pan Sun; Jicheng Qiu; Jianzhong Wang; Lei Yan; Suxia Zhang; Xingyuan Cao
Journal:  Molecules       Date:  2020-10-13       Impact factor: 4.411

6.  Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis.

Authors:  Catia Cilloniz; Raúl Mendez; Héctor Peroni; Carolina Garcia-Vidal; Verónica Rico; Albert Gabarrus; Rosario Menéndez; Antoni Torres; Alex Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-11-12       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.